TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for Patients :~* Older than 18 years old and younger than 80 years old~* ALS patient seen during the diagnostic assessment~Inclusion Criteria for control group :~* Older than 25 years old and younger than 80 years old~* No respiratory or neurologic active pathology~Exclusion Criteria for Patients :~* Bulbar ALS (inability to perform maximal respiratory maneuvers)~* Dementia~* Respiratory failure at diagnosis (arterial carbon dioxide partial pressure (pCO2) \> 45 mmHg)~* Respiratory or neurologic active pathology~Exclusion Criteria for control group :~* Chest wall deformation with spirometric defect

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Patients (Type: None): ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
- Control (Type: None): Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with sickle cell disease ages 18 to 80 years, inclusive Or parents of children (ages 9 months to \<18 years) whose child has not started Hydroxyurea~* Patients who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in past 12 months. Or parents of children who have made a past decision to not obtain treatment with Hydroxyurea or who have not obtained treatment with Hydroxyurea in the past 12 months.~* Patients or parents of children who's doctor identifies the patient/child as someone who should be on Hydroxyurea~* All participants will be able to comprehend English~* Subjects will have access to the internet from iPad, smart phone, or personal computer~* For the cognitive interviews participants will not be eligible to consider hydroxyurea as a treatment option~Exclusion Criteria:~* Patient who has already made a decision to begin and has started Hydroxyurea. Or parent who has already made a decision for their child to begin and the child has started Hydroxyurea.~* Participated in prior Decision Aid study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Training for use of web based Decision Aid (Type: EXPERIMENTAL): Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
- No training for use of web based Decision Aid (Type: PLACEBO_COMPARATOR): Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ACS as defined by a patient who has cardiac chest discomfort and a troponin (cTnT) elevation of greater than 0.1 ng/mL.~* Pt. who is s/p CABG~* Patients with chronic coronary artery disease will be recruited as defined as past history of myocardial infarction, percutaneous coronary intervention, CABG, or history of coronary artery disease documented in the medical record.~* Anemia as defined by HCT between 21%-30%.~Exclusion Criteria:~* Patients with stage III/IV heart failure~* Patients who are actively bleeding requiring immediate transfusion.~* Pregnant patients will be excluded.~* Patients taking sildenafil (Viagra) or other drugs like it, such as vardenafil (Levitra), or tadalafil (Cialis) within 48 hours before the study.~* Patients on iv nitroglycerine infusion.~* Patients who present with ACS or CABG surgery and who are hemodynamically unstable or require immediate revascularization.~* Patients who have received a blood transfusion 24 hours prior to the start of the study.~* Patients with a HCT of \< 21% and those that have chest tube drainage greater then 30 mL/h will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- RBC transfusion (Type: ACTIVE_COMPARATOR): None
- Normal saline infusion (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects undergoing elective laparoscopic gynecologic surgery~2. Patients with chronic pelvic pain defined as pain that has persisted for more than 6 months in duration which is localized to the pelvis, anterior abdominal wall, lower back or buttocks and has leads to functional disability or medical care1~3. Patients requiring opioids daily for \>1 month~4. Consenting adults age 18-80~5. American Society of Anesthesiologists (ASA) Physical Status classification II to ASA III~Exclusion Criteria:~1. Patient refusal~2. Chronic Kidney disease (Creatinine\>2)~3. Patients treated with methadone~4. Known allergy or adverse effect of ketamine or magnesium~5. Patient unable to give informed consent~6. Patient with limited or no English fluency~7. Uncontrolled hypertension

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine plus Magnesium sulfate (Type: ACTIVE_COMPARATOR): Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline (NaCl 0.9%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. ALS-specific: Diagnosis of ALS based on clinical manifestations.~2. ALS-specific: Clinically diagnosed possible, laboratory supported probable, probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology revised El Escorial criteria.~3. ALS-specific: Patients receiving riluzole have been on a stable dose for a minimum of 30 days.~4. ALS-specific: Patients on edaravone have received a minimum of 1 cycle (28 days).~5. ALS-specific: Patients discontinuing riluzole or edaravone had the last dose administered ≥1 month prior to Screening.~6. FTD-specific: Must have Global Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR® plus NACC FTLD) score of 0.5 or 1.~7. FTD-specific: Able to undergo periodic magnetic resonance imaging (MRI) of the brain. Participants with mixed phenotype (ALS and FTD) need not undergo MRI if their ALS symptoms prevent it.~8. Mixed-phenotype: Patients who are mixed phenotype (ALS and FTD) must meet both the ALS-specific and FTD-specific criteria.~Exclusion Criteria:~1. Clinically significant medical finding on the physical examination other than C9orf72-associated ALS or FTD that, in the judgment of the Investigator, will make the patient unsuitable for participation in, and/or completion of the trial procedures~2. Received any other investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Received an investigational oligonucleotide, within the past 6 months or 5 half-lives of the drug, whichever is longer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- WVE-004 (Dose A) or placebo (Type: EXPERIMENTAL): None
- WVE-004 (Dose B) or placebo (Type: EXPERIMENTAL): None
- WVE-004 (Dose C) or placebo (Type: EXPERIMENTAL): None
- WVE-004 (Dose D) or placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intermittent Oro-esophageal Tube vs Nasogastric Tube in Tracheostomized Patients With Intracerebral Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meeting the diagnostic criteria for Intracerebral Hemorrhage.~* with placement of a tracheotomy tube.~* requiring enteral nutrition support.~* age over 18 years.~* able to cooperate with treatment and questionnaire investigation, (Generally with a Mini-Mental State Examination (MMSE) score ≥ 24) .~Exclusion Criteria:~* combined with tumors in the head, neck, esophagus, or gastrointestinal tract~* an abnormal structure observed in the oral, pharyngeal, nasal regions or esophagus~* with unstable vital signs or severe dysfunction of organs including heart, liver, lungs, or kidneys~* with severe hemorrhagic disease or bleeding tendency; 5) with contraindications for enteral nutrition~* with dysphagia caused by non-stroke-related reasons in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The observation group (Type: EXPERIMENTAL): The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~For the observation group, the nasogastric tube was removed, and Intermittent oro-esophageal tube feeding was initiated for nutrition support within 4 hours after completing the admission assessment, following the standard Intermittent oro-esophageal tube feeding procedure.
- The control group (Type: ACTIVE_COMPARATOR): The patients were provided with 1) basic treatment including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control, and 2) comprehensive rehabilitation therapy including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.~Patients in the control group were provided with nutrition support by the indwelling nasogastric tube. The entire feeding process strictly followed the standardized procedure for nasogastric feeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years.~* Creatinine clearance ≤ 60 ml/min by the Cockcroft-Gault equation~* Patients not anticipated to go on dialysis or have renal transplantation in the next 6 months~* Ability to provide informed consent~* Life expectancy greater than 12 months~Exclusion Criteria:~* Diabetes mellitus or a fasting blood glucose ≥ 110 mg/dL~* Acute renal failure~* Class 3 or 4 heart failure~* Liver failure, ascites, or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) two times the upper limit of normal~* Hemoglobin less than 9 mg/dL~* Multiple myeloma~* Premenopausal women not using at least 1 form of birth control~* Pregnant or nursing women~* Prisoners~* Known allergy to pioglitazone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
- Pioglitazone (Type: ACTIVE_COMPARATOR): Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent;~* Subject is ≥ 18 years of age at time of screening;~* Subject has an extra-facial homogenous Port Wine Stain (PWS);~* The PWS is large enough in size to fit one of the templates~* Subject has not received any laser treatment of the PWS in the last 3 months (in the treatment area);~* The PWS has a minimal erythema grading score of 3 (on a 4 point scale) in the opinion of the investigator;~* Screening blood safety values are within normal parameters or regarded as not clinically significant in the opinion of the investigator.~Exclusion Criteria:~* PWS with a nodular/hypertrophic component in the treatment area;~* PWS on cosmetically unacceptable locations in the opinion of the investigator;~* For women: pregnant or breast feeding during the treatment period;~* Women of child-bearing potential, unless they are using adequate contraceptive measures~* Subject is known to have immune deficiency, or is immune compromised~* Known allergy to sirolimus or other constituents of the study medication;~* Incapacitated subjects;~* Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- sirolimus topical 40microgram/cm2 (Type: EXPERIMENTAL): sirolimus topical 40microgram/cm2
- Pulsed Dye Laser + Erbium yag + sirolimus (Type: EXPERIMENTAL): Pulsed Dye Laser + Erbium yag laser + topical sirolimus
- Pulsed Dye Laser + topical sirolimus (Type: EXPERIMENTAL): Pulsed Dye Laser + topical sirolimus
- Pulsed Dye Laser (Type: EXPERIMENTAL): Pulsed Dye Laser

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Hospital Elder Life Program at the Jewish General Hospital

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 65 and over~* admitted to orthopedic ward for hip surgery after a fracture~Exclusion Criteria:~* younger than 65 years of age~* palliative care

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Interventional (Type: OTHER): The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Normoglycemia and Neurological Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-traumatic SAH, ICH, or TBI~* Glasgow Coma Scale between 6 and 14~* admitted to an ICU of University of Louisville Hospital~Exclusion Criteria:~* Patients \<18 and \>80 years~* GCS Motor score \<4 or an overall GCS score of 15~* diabetic patients who suffer from dialysis-dependent diabetic nephropathy~* patients with multiple injuries~* patients who would have been classified as ASA 3 status prior to their acute neurological event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intensive IV Insulin (Type: EXPERIMENTAL): Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
- Conventional Insulin Treatment (Type: ACTIVE_COMPARATOR): Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants born before the complete 32 weeks of gestation~* Signed parental consent~Exclusion Criteria:~* Major congenital anomalies or birth defects

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 1 Day
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fucidin® Cream in the Treatment of Impetigo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a clinical diagnosis of impetigo,~* Patients aged 2-11 years,~* Patients of either sex,~* Patients whose parent(s) has(ve) provided written consent, AND~* Patients with a severity score of 1 for at least one of the following signs: pustules/infected bullae, erythema and infiltration/induration.~Exclusion Criteria:~* Patients with other active inflammatory dermatitis at the area of impetigo,~* Patients with a temperature above 38.5 C rectally (or equivalent), OR~* Patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Fucidin® cream (Type: EXPERIMENTAL): None
- Fucidin® cream vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Raised CBF During CEA on Cognition in DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ability to speak English~* no history of permanent neurological impairment, Axis I psychiatric diagnosis or drug abuse~* scheduled for elective carotid endarterectomy for treatment of carotid artery stenosis~* diagnosed with diabetes mellitus or HbA1c value greater than 10%~Exclusion Criteria:~* younger than 18 yrs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Shunt (Type: ACTIVE_COMPARATOR): Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management.
- Prophylactic Shunt (Type: EXPERIMENTAL): Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility